

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Clover Biopharmaceuticals, Ltd.
三葉草生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2197)

POSTPONEMENT OF BOARD MEETING DATE

Reference is made to the announcement of Clover Biopharmaceuticals, Ltd. (the “**Company**”) dated March 12, 2025 in relation to the meeting of the board of directors (the “**Board**”) of the Company (the “**Board Meeting**”) to be held on Monday, March 24, 2025 for the purpose of, inter alia, considering and approving the annual results of the Company and its subsidiaries for the year ended December 31, 2024 (the “**2024 Annual Results**”), and its publication, and evaluating the payment of a final dividend, if any.

As more time is required to finalise the 2024 Annual Results, the Board hereby announces that the Board Meeting will be postponed from Monday, March 24, 2025 to Monday, March 31, 2025.

By order of the Board
Clover Biopharmaceuticals, Ltd.
Dr. Peng LIANG
Chairman of the Board

Shanghai, PRC, March 24, 2025

As at the date of this announcement, the Board comprises Dr. Peng LIANG and Mr. Joshua G LIANG as executive directors, Dr. Xiaodong WANG, Dr. Donna Marie AMBROSINO and Dr. Ralf Leo CLEMENS as non-executive directors and Dr. Xiaobin WU, Mr. Xiang LIAO, Mr. Jeffrey FARROW and Mr. Thomas LEGGETT as independent non-executive directors.